Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2013 1
2014 1
2015 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, Berraondo P, Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M, Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia JL, Melero I. Schalper KA, et al. Nat Med. 2019 Mar;25(3):470-476. doi: 10.1038/s41591-018-0339-5. Epub 2019 Feb 11. Nat Med. 2019. PMID: 30742120 Clinical Trial.
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N, Eigenbrod S, Grasbon-Frodl EM, Lutz J, Kreth S, Popperl G, Belka C, Kretzschmar HA, Tonn JC, Kreth FW. Thon N, et al. J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):441-6. doi: 10.1136/jnnp.2010.214593. Epub 2010 Sep 22. J Neurol Neurosurg Psychiatry. 2011. PMID: 20861061
BACKGROUND: Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZTMZ). ...CONCLUSION: MGMT promoter methylation has a predominant favourable influence even for the im …
BACKGROUND: Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomi …
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.
Westphal M, Ylä-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z; ASPECT Study Group. Westphal M, et al. Lancet Oncol. 2013 Aug;14(9):823-33. doi: 10.1016/S1470-2045(13)70274-2. Epub 2013 Jul 12. Lancet Oncol. 2013. PMID: 23850491 Clinical Trial.
We assessed the efficacy and safety of a locally applied adenovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine kinase; sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly diagnosed resectable gli …
We assessed the efficacy and safety of a locally applied adenovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-v …
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F. Iaccarino C, et al. Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7. Clin Neurol Neurosurg. 2015. PMID: 25723791
BACKGROUND: Methylation of MGMT promoter has been identified as a favourable predictive factor of benefit from XRT/TMZ TMZ. Patients with non-resectable glioblastoma (GBM) generally exhibit a poor prognosis, even after XRT/TMZ. ...
BACKGROUND: Methylation of MGMT promoter has been identified as a favourable predictive factor of benefit from XRT/TMZ TMZ. Patients with no …
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.
Balaña C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, Capellades J, Gonzalez S, Verger E. Balaña C, et al. Target Oncol. 2014 Dec;9(4):321-9. doi: 10.1007/s11523-014-0305-1. Epub 2014 Jan 15. Target Oncol. 2014. PMID: 24424564 Clinical Trial.
The present trial examined the activity of sunitinib in 12 patients with newly diagnosed, non-resectable glioblastoma. Patients (75 years of age with performance status [PS] 2 and minimental status [MMS] 25) were treated post-biopsy with sunitinib 37.5 mg daily for …
The present trial examined the activity of sunitinib in 12 patients with newly diagnosed, non-resectable glioblastoma. Patient …
Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC. Dillman RO, et al. J Immunother. 2009 Nov-Dec;32(9):914-9. doi: 10.1097/CJI.0b013e3181b2910f. J Immunother. 2009. PMID: 19816190 Clinical Trial.
Despite recent advances, median survival for patients with resectable glioblastoma multiforme (GBM) is only 12 to 15 months. We previously observed minimal toxicity and a 9.0-month median survival after treatment with intralesional autologous lymphokine-activated ki …
Despite recent advances, median survival for patients with resectable glioblastoma multiforme (GBM) is only 12 to 15 months. W …